BRIEF—J&J scores UK funding for Imbruvica

Johnson & Johnson has secured a positive reimbursement decision in the UK for Imbruvica (ibrutinib), in the first-line treatment of chronic lymphocytic leukemia (CLL).

The therapy will be available to treat people with CLL, in combination with venetoclax, across England and Wales through the UK’s national healthcare provider.

Amanda Cunnington, director of patient access at J&J’s pharma subsidiary, Janssen, said: “We are delighted with NICE’s decision to recommend ibrutinib plus venetoclax, especially since it has been recommended for use in the entire indicated population in England.”

She added: “We look forward to seeing eligible patients benefit from this treatment, and remain committed to advancing innovations in blood cancer across the world.”